The story has been corrected to reflect that the name of one of the checkpoint inhibitor therapies is PD-L1 and the name of MioDx's immunosequencing platform is called ClonoMap. Our apologies for the errors. 

NEW YORK (360Dx) – Cancer biomarker firm MioDx on Thursday said it has exclusively licensed technologies from the University of California, San Francisco related to monitoring patient response to immunotherapies.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.